Opamtistomig (PD-L1/4-1BB Bispecific Antibody) Advances to Expansion Stage in Phase II First-Line Gastric Cancer Study
Dr. Charles Cai, Chief Medical Officer of Leads Biolabs, stated: “Gastric cancer represents a significant unmet medical need, particularly for patients with low PD-L1 expression who may derive limited benefit from current first-line immunotherapy combinations. The encouraging preliminary signals observed in the safety lead-in support advancing opamtistomig into a randomized expansion stage, where its efficacy and safety will be evaluated against an established immunotherapy-based regimen. We look forward to generating more robust clinical evidence to determine whether opamtistomig can offer a differentiated first-line treatment option and improve outcomes for patients with advanced gastric cancer.”
Share:
More News
“The positive outcome of our pre-IND interactions with the FDA reinforces the development pathway for MaaT034 and supports its continued advancement toward the clinic. It also represents an important step in MaaT Pharma’s expansion into immuno-oncology, highlighting the broader potential of our first in class co-cultivated microbiome donor-independent platform across
“Patients with metastatic RAS G12D non-squamous NSCLC, occurring in approximately 4% of cases, represent an underserved population, with no approved targeted treatment options. Initial clinical data evaluating zoldonrasib in combination with standard of care pembrolizumab and platinum doublet chemotherapy in patients with previously untreated metastatic RAS G12D non-squamous NSCLC showed
“At Georgiamune, we are focused on uncovering novel mechanisms that control immune-cell function and translating that biology into first-in-class medicines across autoimmune disease and oncology,” said Samir N. Khleif, M.D., Founder and Chief Executive Officer of Georgiamune. “GIM-621 is one of multiple programs to emerge from that work, alongside three
“Our team’s outstanding execution has enabled us to rapidly advance three programs into the clinic in 2026 and make significant progress in developing next-generation IO, ADC and combination therapies. Together with our partner, Kelun-Biotech, we have achieved seven IND clearances to date, and by mid-2027, we expect more than 2,000